Inhibrx Biosciences, Inc. (INBX)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $1.23B
Last updated: Nov 17, 2026 at 11:05 AM ET
Inhibrx Biosciences, Inc. (INBX) Financials: Revenue, Profit and Cash Flow
Inhibrx Biosciences reported revenue of $1.30M for the fiscal year ended Dec 31, 2025, up 550.0% from the year before. That year, net income was -$140.06M with a net margin of -10773.5%, operating cash flow was -$129.79M and free cash flow was -$129.82M. The quarter ended Sep 30, 2026 had revenue of $2.00M and net income of -$38.73M.
Revenue and Margins
Over the 9 years to Dec 2025, revenue fell from $6.67M, a compound annual decline of 16.6%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $1.30M | +550.0% | 100.0% | -10386.5% | -10773.5% |
| Dec 2024 | $200.00K | -88.9% | 100.0% | -165724.0% | 843786.0% |
| Dec 2023 | $1.80M | -17.9% | 100.0% | -12178.9% | -13408.9% |
| Dec 2022 | $2.19M | -69.2% | -4926.7% | -5890.4% | -6625.3% |
| Dec 2021 | $7.13M | -44.4% | 62.3% | -1074.6% | -1147.6% |
| Dec 2020 | $12.81M | +40.9% | -473.8% | -526.6% | -590.5% |
| Dec 2019 | $9.09M | +21.2% | -426.9% | -480.7% | -565.3% |
| Dec 2018 | $7.50M | -5.7% | -346.1% | -393.5% | -415.5% |
| Dec 2017 | $7.95M | +19.2% | -220.9% | -248.2% | -244.6% |
| Dec 2016 | $6.67M | N/A | -154.9% | -182.2% | -124.0% |
Income Statement
In the fiscal year ended Dec 2025, the company posted a net loss after a profit the year before. In the quarter ended Sep 2026, the net loss widened from the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.30M | $200.00K | $1.80M | $2.19M | $7.13M | $12.81M | $9.09M | $7.50M | $7.95M | $6.67M |
| Cost of revenue | $0 | $0 | $0 | $110.19M | $2.69M | $73.50M | $47.91M | $33.45M | $25.51M | $16.99M |
| Gross profit | $1.30M | $200.00K | $1.80M | -$107.99M | $4.44M | -$60.69M | -$38.81M | -$25.95M | -$17.56M | -$10.32M |
| Research and development | $113.03M | $203.74M | $191.64M | $110.19M | $71.44M | $73.50M | $47.91M | $33.45M | $25.51M | $16.99M |
| Operating income | -$135.03M | -$331.45M | -$219.22M | -$129.12M | -$76.56M | -$67.44M | -$43.71M | -$29.51M | -$19.73M | -$12.15M |
| Net income | -$140.06M | $1.69B | -$241.36M | -$145.23M | -$81.77M | -$75.64M | -$51.40M | -$31.16M | -$19.44M | -$8.27M |
| EBITDA | -$130.48M | $1.69B | -$213.71M | -$125.82M | -$75.37M | -$63.80M | -$42.60M | -$28.77M | -$19.30M | -$11.89M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.00M | $0 | $0 | $0 | $0 | $1.30M | $0 | $100.00K | $0 | $100.00K | $0 | $1.63M |
| Gross profit | $2.00M | $0 | $0 | -$564.00K | $0 | $1.30M | $0 | $100.00K | $0 | $100.00K | $0 | $1.34M |
| Operating income | -$31.73M | -$32.15M | -$30.93M | -$30.92M | -$33.81M | -$27.39M | -$42.90M | -$49.93M | -$46.80M | -$160.90M | -$73.83M | -$88.29M |
| Net income | -$38.73M | -$36.65M | -$33.44M | -$32.83M | -$35.26M | -$28.65M | -$43.31M | -$47.87M | -$43.86M | $1.86B | -$78.71M | -$93.60M |
Balance Sheet
As of Dec 2025, cash and equivalents exceeded total debt of $102.89M by $21.34M.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $146.48M | $180.77M | $307.89M | $290.88M | $150.45M | $143.74M | $26.49M | $9.98M | $17.25M | $21.27M |
| Current assets | $132.83M | $160.40M | $295.36M | $280.49M | $139.11M | $132.17M | $15.56M | $5.66M | $15.44M | $20.41M |
| Cash and equivalents | $124.22M | $152.60M | $277.92M | $273.87M | $131.30M | $128.66M | $11.54M | $2.10M | $13.47M | $20.02M |
| Total liabilities | $138.49M | $47.18M | $264.39M | $232.82M | $98.07M | $68.27M | $120.06M | $67.63M | $39.67M | $20.03M |
| Short-term debt | $2.33M | $1.59M | $2.06M | $1.86M | $1.67M | $1.50M | $4.67M | $5.93M | $5.17M | $4.26M |
| Long-term debt | $100.56M | $0 | $206.97M | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Shareholder equity | $7.99M | $133.58M | $43.50M | $58.06M | $52.38M | $75.47M | -$93.57M | -$57.64M | -$28.77M | -$9.25M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $220.29M | $154.22M | $183.97M | $146.48M | $177.47M | $212.12M | $242.64M | $180.77M | $222.56M | $258.42M | $288.58M | $307.89M |
| Total liabilities | $306.17M | $207.20M | $205.00M | $138.49M | $140.64M | $143.56M | $148.20M | $47.18M | $44.09M | $39.05M | $277.01M | $264.39M |
| Cash and equivalents | $199.47M | $133.34M | $161.66M | $124.22M | $153.09M | $186.57M | $216.52M | $152.60M | $196.33M | $226.86M | $252.48M | $277.92M |
| Shareholder equity | -$85.88M | -$52.98M | -$21.04M | $7.99M | $36.83M | $68.56M | $94.44M | $133.58M | $178.47M | $219.37M | $11.57M | $43.50M |
Cash Flow
Operating cash flow was negative in the fiscal year ended Dec 2025.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$129.79M | -$194.41M | -$193.31M | -$115.30M | -$80.32M | -$47.97M | -$32.08M | -$23.09M | -$18.75M | -$18.11M |
| Capital expenditures | $31.00K | $2.60M | $4.59M | $686.00K | $864.00K | $1.36M | $1.81M | $1.43M | $1.34M | $215.00K |
| Free cash flow | -$129.82M | -$197.01M | -$197.90M | -$115.99M | -$81.19M | -$49.33M | -$33.89M | -$24.52M | -$20.09M | -$18.32M |
| Dividends paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $828.00K | $1.38M | N/A |
| Share repurchases | N/A | N/A | $355.00K | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Investing cash flow | -$28.00K | -$2.60M | -$4.59M | -$686.00K | -$809.00K | -$1.36M | -$1.81M | -$1.43M | -$1.34M | -$215.00K |
| Financing cash flow | $101.45M | $71.68M | $201.96M | $258.55M | $83.77M | $166.46M | $43.33M | $13.15M | $13.54M | $28.77M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$34.60M | -$29.92M | -$38.03M | -$30.12M | -$33.82M | -$29.95M | -$35.90M | -$43.72M | -$30.28M | -$57.36M | -$63.05M | -$56.82M |
| Capital expenditures | $29.00K | N/A | $0 | $0 | $10.00K | $0 | $21.00K | $16.00K | $247.00K | $1.22M | $1.12M | $3.44M |
| Free cash flow | -$34.63M | N/A | -$38.03M | -$30.12M | -$33.83M | -$29.95M | -$35.92M | -$43.74M | -$30.53M | -$58.57M | -$64.17M | -$60.26M |
Frequently Asked Questions About INBX
What is Inhibrx Biosciences' annual revenue?
Inhibrx Biosciences reported revenue of $1.30M for the fiscal year ended Dec 31, 2025.
How fast is Inhibrx Biosciences' revenue growing?
Revenue was up 550.0% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was -16.0%.
Is Inhibrx Biosciences profitable?
No. Inhibrx Biosciences reported net income of -$140.06M for the fiscal year ended Dec 31, 2025, with a net margin of -10773.5%.
How much free cash flow does INBX generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of -$129.79M minus capital expenditures of $31.00K produced free cash flow of -$129.82M.
How much debt does Inhibrx Biosciences have?
The balance sheet dated Dec 31, 2025 reported long-term debt of $100.56M, short-term debt of $2.33M and cash and equivalents of $124.22M.
INBX pages: Overview, Earnings, Forecast, Financials, Competitors